Xencor Inc Dossier - Source-backed chat

Xencor Inc

XNCRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.89

Intrinsic Value $16.45median of 2 methodsbased on filings through 30 Jun 2026

Market Price $24.95Price as of 30 Sep 2026

OvervaluedIntrinsic value is 34% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.9B

Enterprise Value $1.9B

Shares Outstanding 75.8M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Xencor Inc. represents a compelling clinical-stage biopharmaceutical investment backed by a robust, validated protein engineering platform (XmAb) and a well-funded balance sheet. The company's lead oncology asset, XmAb819 (ENPP3 x CD3), has demonstrated encouraging early anti-tumor activity (25% ORR in target dose range) and a manageable safety profile in heavily pretreated ccRCC patients, with key expansion cohort data expected in 2H 2026 to support a planned 2027 pivotal trial. Furthermore, Xencor is rapidly advancing a high-potential autoimmune pipeline led by XmAb942 (anti-TL1A) in a Phase 2b study for ulcerative colitis, and XmAb412 (TL1A x IL23p19), which is set to enter the clinic in 3Q 2026. With $541.8 million in cash and marketable debt securities as of Q1 2026, Xencor possesses a strong cash runway extending into mid-2028, significantly mitigating near-term financing risks while it executes on multiple high-impact clinical catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.00

Mean target$29.00

High · most bullish analyst$44.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is driven by clinical setbacks, such as elevated rates of severe cytokine release syndrome (CRS) or dosing errors in the XmAb819 cohorts, leading to trial delays or a heavily discounted asset value. Furthermore, if the XENITH-UC trial of XmAb942 faces enrollment delays or fails to show competitive efficacy compared to first-generation anti-TL1A therapies, the pipeline's commercial viability would be severely compromised, forcing the stock to trade closer to its cash floor.

Base CaseCentral scenario

The base case assumes successful execution of the Phase 1 expansion cohorts for XmAb819, confirming a recommended Phase 3 dose in 2H 2026 and enabling the initiation of a pivotal study in ccRCC in 2027. It also assumes that the Phase 2b XENITH-UC study of XmAb942 progresses on schedule with a supportive blinded interim analysis at year-end 2026, and that the first-in-human study of XmAb412 begins in 3Q 2026. Financial stability is maintained through steady non-cash royalties from partners and the resolution of the Alexion royalty dispute, keeping the cash runway intact through mid-2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary, highly versatile XmAb protein engineering platform with multiple partner-marketed products validating the technology.
Strong cash position of $541.8 million (as of March 31, 2026) providing a runway into mid-2028 and reducing near-term dilution risk.
Lead oncology candidate XmAb819 (ENPP3 x CD3) has shown a 25% ORR and 70% disease control rate in heavily pretreated ccRCC patients.
Differentiated autoimmune pipeline with XmAb942 (anti-TL1A) designed for a convenient 12-week subcutaneous dosing interval, and XmAb412 dual-targeting TL1A and IL-23p19.

Key Investment Risks

Clinical development risk, particularly the potential for severe cytokine release syndrome (CRS) or other toxicities typical of T-cell engagers.
Intense competition in both the oncology (ccRCC) and autoimmune (anti-TL1A / IBD) therapeutic landscapes.
Dependence on partner execution and royalty streams, as highlighted by the recent royalty dispute with Alexion over Ultomiris sales.

Thesis Invalidation Triggers

Failure of XmAb819 expansion cohort data in 2H 2026 to support a recommended Phase 3 dose or show competitive efficacy.
Safety-related clinical holds or severe adverse events in the T-cell engager or bispecific programs.
Negative or inconclusive interim analysis results for the XENITH-UC study of XmAb942 around year-end 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.